Turning Japanese for pharmaceuticals group
STAFFORDSHIRE pharmaceuticals group Clinigen has launched a Japanese business.
The establishment of Clinigen KK further expands the Burton upon Trent group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015.
Alongside the launch, Clinigen KK will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir® (foscarnet sodium) back from Nobel Pharma on November 1, 2016. Nobel Pharma has been the distribution partner for Foscavir in Japan since 2011.
Clinigen employs over 500 people globally, across 11 locations.
Shaun Chilton, chief executive officer-designate, said: “We are focused on building our market leadership positions by expanding in key geographic regions to drive sustained organic growth and better address unmet patient needs for access to critical medicines.
“The opening of our Japanese business helps support our goals and will enable us to effectively serve the Japanese market by supplying our own products, beginning with Foscavir.
“At a time when many pharmaceutical and biotechnology companies are looking for specialist partners to work with them in Asia, the opening of our Japanese office gives us more opportunities to provide customers with our global expertise combined with local knowledge.”
